Researchers at UC Davis have found that the drug bortezomib effectively treats chronic graft-versus-host disease , a common and debilitating side effect from allogeneic hematopoietic stem cell transplants. The trial showed that bortezomib provides better outcomes than existing treatments and does not impair the immune response against residual cancer cells, or the graft-versus-tumor effect .
http://ift.tt/1tya5DT
http://ift.tt/1tya5DT
No comments:
Post a Comment